Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?

Summary

Capricor (CAPR) stock closed 58% higher following what the headline describes as an FDA lifeline. The article discusses whether approval is back on track but lacks specific details about the underlying regulatory decision or drug program.